These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28011908)

  • 21. Vaginal microbiome-hormonal contraceptive interactions associate with the mucosal proteome and HIV acquisition.
    Noël-Romas L; Perner M; Molatlhegi R; Farr Zuend C; Mabhula A; Hoger S; Lamont A; Birse K; Berard A; McCorrister S; Westmacott G; Leslie A; Poliquin V; Heffron R; McKinnon LR; Burgener AD
    PLoS Pathog; 2020 Dec; 16(12):e1009097. PubMed ID: 33362285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Norethisterone Enanthate Increases Mouse Susceptibility to Genital Infection with Herpes Simplex Virus Type 2 and HIV Type 1.
    Quispe Calla NE; Vicetti Miguel RD; Torres AR; Trout W; Gabriel JM; Hatfield AM; Aceves KM; Kwiek JJ; Kaur B; Cherpes TL
    Immunohorizons; 2020 Feb; 4(2):72-81. PubMed ID: 32047094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Female Genital Tract Cytokine and Microbiota Signatures Induced by Initiation of Intramuscular DMPA and NET-EN Hormonal Contraceptives - a Prospective Cohort Analysis.
    Dabee S; Tanko RF; Brown BP; Bunjun R; Balle C; Feng C; Konstantinus IN; Jaumdally SZ; Onono M; Nair G; Palanee-Phillips T; Gill K; Baeten JM; Bekker LG; Passmore JS; Heffron R; Jaspan HB; Happel AU
    Front Immunol; 2021; 12():760504. PubMed ID: 34956191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial.
    Bunjun R; Ramla TF; Jaumdally SZ; Noël-Romas L; Ayele H; Brown BP; Gamieldien H; Harryparsad R; Dabee S; Nair G; Onono M; Palanee-Phillips T; Scoville CW; Heller KB; Baeten JM; Bosinger SE; Burgener A; Passmore JS; Jaspan H; Heffron R
    Clin Infect Dis; 2022 Nov; 75(11):2000-2011. PubMed ID: 35941737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in key vaginal bacteria among postpartum African women initiating intramuscular depot-medroxyprogesterone acetate.
    Whitney BM; Guthrie BL; Srinivasan S; Tapia K; Muriuki EM; Chohan BH; Wallis JM; Liu C; McClelland RS; Fredricks DN; Roxby AC
    PLoS One; 2020; 15(3):e0229586. PubMed ID: 32134931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection.
    Quispe Calla NE; Vicetti Miguel RD; Boyaka PN; Hall-Stoodley L; Kaur B; Trout W; Pavelko SD; Cherpes TL
    Mucosal Immunol; 2016 Nov; 9(6):1571-1583. PubMed ID: 27007679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of contraceptive initiation on vaginal microbiota.
    Achilles SL; Austin MN; Meyn LA; Mhlanga F; Chirenje ZM; Hillier SL
    Am J Obstet Gynecol; 2018 Jun; 218(6):622.e1-622.e10. PubMed ID: 29505773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
    Dragoman MV; Gaffield ME
    Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial.
    Chinula L; Nelson JAE; Wiener J; Tang JH; Hurst S; Tegha G; Msika A; Ellington S; Hosseinipour MC; Mataya R; Haddad LB; Kourtis AP
    Contraception; 2018 Sep; 98(3):193-198. PubMed ID: 29746813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
    Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception.
    Heffron R; Parikh UM; Penrose KJ; Mugo N; Donnell D; Celum C; Mellors JW; Baeten JM;
    AIDS Behav; 2017 Jul; 21(7):2173-2179. PubMed ID: 27699594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Hormonal Contraception on Cervicovaginal Mucosal End Points Associated with HIV Acquisition.
    Thurman A; Chandra N; Schwartz JL; Brache V; Chen BA; Asin S; Rollenhagen C; Herold BC; Fichorova RN; Hillier SL; Weiner DH; Mauck C; Doncel GF
    AIDS Res Hum Retroviruses; 2019 Sep; 35(9):853-864. PubMed ID: 30997816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Responding to the ECHO trial results: modelling the potential impact of changing contraceptive method mix on HIV and reproductive health in South Africa.
    Smith JA; Beacroft L; Abdullah F; Buthelezi B; Makua M; Morroni C; Ramjee G; Velasquez C; Hallett TB
    J Int AIDS Soc; 2020 Oct; 23(10):e25620. PubMed ID: 33030312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Research gaps in defining the biological link between HIV risk and hormonal contraception.
    Murphy K; Irvin SC; Herold BC
    Am J Reprod Immunol; 2014 Aug; 72(2):228-35. PubMed ID: 24548147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate Users.
    Thurman AR; Schwartz JL; Brache V; Chen BA; Chandra N; Kashuba ADM; Weiner DH; Mauck C; Doncel GF
    J Acquir Immune Defic Syndr; 2019 Jan; 80(1):79-88. PubMed ID: 30212395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
    Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
    Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential Elevation of Inflammation and CD4
    Omollo K; Lajoie J; Oyugi J; Wessels JM; Mwaengo D; Kimani J; Kaushic C; Fowke KR
    Front Immunol; 2020; 11():598307. PubMed ID: 33717049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone density in long term users of depot medroxyprogesterone acetate.
    Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
    Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093.
    Watts DH; Park JG; Cohn SE; Yu S; Hitti J; Stek A; Clax PA; Muderspach L; Lertora JJ
    Contraception; 2008 Feb; 77(2):84-90. PubMed ID: 18226670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cervical cancer risk and use of depot-medroxyprogesterone acetate in Costa Rica.
    Oberle MW; Rosero-Bixby L; Irwin KL; Fortney JA; Lee NC; Whatley AS; Bonhomme MG
    Int J Epidemiol; 1988 Dec; 17(4):718-23. PubMed ID: 2976059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.